Phaseline

Targets › RBM39

RBM39 (RNA-binding protein 39): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.

RNA-binding protein that acts as a pre-mRNA splicing factor. Acts by promoting exon inclusion via regulation of exon cassette splicing. (UniProt, Q14498)

Open in Phaseline: the race on RBM39, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SEED TherapeuticsST-01156
RBM39 degrader
RBM39Phase 1Advanced Solid TumorsDec 2029

Conditions

Advanced Solid Tumors (1)

Modalities

small molecule (1)

Companies

SEED Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.